CG Oncology (CGON) Interest Coverage Ratio: History & Chart

CG Oncology Inc.(CGON)

Biotechnology · Dallas, TX

$69.17+0.46 (+0.67%)

Delayed quote: Oct 6, 2026, 9:30 AM EDT

About CG Oncology Inc.

CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company’s product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC. It also develops cretostimogene monotherapy for intermediate-risk NMIBC following TURBT, which is in phase 3 PIVOT-006 clinical trials to assess the safety and efficacy of adjuvant cretostimogene; and cretostimogene monotherapy for high-risk NMIBC in phase 2 CORE-008 clinical trials to assess the safety and clinical outcomes of cretostimogene in treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC. The company was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. CG Oncology, Inc. was founded in 2010 and is headquartered in Irvine, California.

Dallas, TX

142 employees

cgoncology.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Arthur Kuan

View full financials

NAME	MARKET CAP	INTEREST COVERAGE RATIO	TTM	3Y	5Y
CG Oncology Inc. (CGON)	$6.10B	N/A	N/A	N/A	N/A
Ligand Pharmaceuticals Incorporated (LGND)vs ›	$6.20B	10.01x	10.01x	9.97x	7.31x
Kiniksa Pharmaceuticals International, plc (KNSA)vs ›	$5.79B	N/A	N/A	N/A	N/A
Iovance Biotherapeutics, Inc. (IOVA)vs ›	$6.34B	N/A	N/A	N/A	N/A
Amneal Pharmaceuticals, Inc. (AMRX)vs ›	$6.52B	1.75x	1.35x	1.23x	1.08x
CRISPR Therapeutics AG (CRSP)vs ›	$5.84B	N/A	N/A	N/A	N/A
GRAIL Inc. (GRAL)vs ›	$6.85B	N/A	N/A	N/A	N/A
Hims & Hers Health, Inc. (HIMS)vs ›	$6.69B	N/A	N/A	N/A	N/A
Chemed Corporation (CHE)vs ›	$6.71B	193.28x	199.58x	145.92x	155.47x
Doximity, Inc. (DOCS)vs ›	$5.42B	N/A	N/A	N/A	N/A

NAME

MARKET CAP

INTEREST COVERAGE RATIO

TTM

CG Oncology Inc. (CGON)

$6.10B

N/A

Ligand Pharmaceuticals Incorporated (LGND)vs ›

$6.20B

10.01x

9.97x

7.31x